OncoTherapy Science (FRA:30O) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:30O OncoTherapy Science Inc FRA:30O
49 GF Score
Price €0.09
GF Value €0.08
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation

OncoTherapy Science  (FRA:30O) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

OncoTherapy Science Cyclically Adjusted PS Ratio Related Terms

OncoTherapy Science Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Cyclically Adjusted PS Ratio Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.22 10.48 4.20 6.48 4.13

OncoTherapy Science Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.67 4.82 3.23 3.65 2.79

FRA:30O vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, OncoTherapy Science's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoTherapy Science Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Cyclically Adjusted PS Ratio falls into.


FRA:30O
49GF Score
OncoTherapy Science Inc FRA:30O
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

OncoTherapy Science's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, OncoTherapy Science's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.002/113.6000*113.6000
=0.002

Current CPI (Jun. 2026) = 113.6000.

OncoTherapy Science Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.002 98.000 0.002
201612 0.012 98.400 0.014
201703 0.003 98.100 0.003
201706 0.011 98.500 0.013
201709 0.000 98.800 0.000
201712 0.000 99.400 0.000
201803 0.000 99.200 0.000
201806 0.001 99.200 0.001
201809 0.001 99.900 0.001
201812 0.012 99.700 0.014
201903 0.002 99.700 0.002
201906 0.003 99.800 0.003
201909 0.003 100.100 0.003
201912 0.003 100.500 0.003
202003 0.007 100.300 0.008
202006 0.002 99.900 0.002
202009 0.003 99.900 0.003
202012 0.003 99.300 0.003
202103 0.008 99.900 0.009
202106 0.004 99.500 0.005
202109 0.006 100.100 0.007
202112 0.004 100.100 0.005
202203 0.033 101.100 0.037
202206 0.014 101.800 0.016
202209 0.005 103.100 0.006
202212 0.007 104.100 0.008
202303 0.016 104.400 0.017
202306 0.005 105.200 0.005
202309 0.006 106.200 0.006
202312 0.003 106.800 0.003
202403 0.004 107.200 0.004
202406 0.003 108.200 0.003
202409 0.003 108.900 0.003
202412 0.008 110.700 0.008
202503 0.004 111.100 0.004
202506 0.004 111.700 0.004
202509 0.004 112.000 0.004
202512 0.003 113.000 0.003
202603 0.003 112.700 0.003
202606 0.002 113.600 0.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is OncoTherapy Science (FRA:30O) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of €0.09 is trading 14.4% above its estimated GF Value™ of €0.08.

Key valuation signals for FRA:30O:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.08 vs. price of €0.09 (14.4% above fair value)
  • GF Score™: 49/100 with 1 warning sign

No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 4564:Japan
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
49GF Score

Get the complete analysis for FRA:30O

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.08
GF Value